Biomarkers of peritoneal fibrosis in patients with peritoneal dialysis were investigated by transcriptomics of exfoliated cells and metabolomics of exfoliated cells in peritoneal dialysis
Patients on peritoneal dialysis: a. Age 18-75 years; b. Regular abdominal dialysis due to uremia> 3 months; c. Signed informed consent
Hemodialysis patients: a. Age 18-75 years; b. Due to regular hemodialysis due to uremia> 3 months old, allogeneic kidney transplantation is planned; c. Signed informed consent
Patients with normal renal function: a. Age 18-75 years; b. Proposed elective inguinal hernia repair surgery; c. Signed informed consent.
Patients on peritoneal dialysis: a. History of peritonitis in the past 3 months; b. History of abdominal tumors with peritoneal metastases
Hemodialysis patients: a. Previous abdominal dialysis history; b. History of abdominal tumors with peritoneal metastases Patients with normal renal function: a. History of chronic kidney disease; b. History of abdominal tumors with peritoneal metastases
Peritoneal dialysis patients, hemodialysis control patients, and normal renal function control patients
Case-control
Cross-sectional
Not listed
(1) RNA-seq transcriptomics of exfoliated cells; (2) LC-MS metabolomics of permeable supernatant.
Extract RNA from exfoliated cells in exupine, perform mRNA-seq analysis, collect exudate supernatant at the same time, perform metabolome analysis based on mass spectrometry detection, machine learning analysis of multi-omics data, and explore sensitive biomarkers for predicting peritoneal fibrosis based on the evaluation data of peritoneal samples of some patients.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
